Clinical trials: Lymphoma, Malignant
Diffuse Large Cell B-lymphoma
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT06854445
- Testing
- TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
- Where
- 24 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Peripheral T Cell Lymphoma
A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of SHC014748M in patients with relapsed or refractory relapsed or refractory Peripheral T Cell Lymphoma.
- Trial name
- NCT04470141
- Testing
- SHC014748M treatment
- Volunteers
- 130 people
- Sponsor
- Nanjing Sanhome Pharmaceutical, Co., Ltd.
GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL)
Phase I Study of Milatuzumab for Graft Versus Host Disease
This study will assess the safety and tolerability of milatuzumab (IMMU-115) when added to a standard regimen to prevent Graft vs. Host Disease (GVHD) in patients with hematologic malignancies undergoing stem cell transplant.
- Conditions
- GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL), Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML)
- Trial name
- NCT01663766
- Testing
- milatuzumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gilead Sciences
Primary Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
In this study, the safety and preliminary efficacy of GNC-038 in patients with r relapsed or refractory primary central nervous system lymphoma (PCNSL) and relapsed or refractory secondary central nervous system lymphoma (SCNSL)…
- Trial name
- NCT05485753
- Testing
- GNC-038
- Where
- 4 sites in China
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Dementia Moderate, Dementia, Mild
Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD).
- Conditions
- Dementia Moderate, Dementia, Mild, Alzheimer Disease
- Trial name
- XanaMIA (NCT06125951)
- Testing
- Xanamem
- Where
- 34 sites in United States, Australia
- Volunteers
- 247 people
- Sponsor
- Actinogen Medical
T-lymphoblastic Lymphoma, NK/T Cell Lymphoma
CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia.
- Conditions
- T-lymphoblastic Lymphoma, NK/T Cell Lymphoma, Acute Lymphocytic Leukemia
- Trial name
- NCT04004637
- Testing
- CD7 CAR-T cells infusion
- Where
- China
- Volunteers
- 10 people
- Sponsor
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Hodgkin's Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL)
A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68)
The primary objective of the study is to evaluate the objective response rate (ORR), by cohort, rrcHL and rrPMBCL, as assessed by the investigator according to Lugano classification criteria 2014 in participants treated with…
- Trial name
- NCT04875195
- Testing
- Pembrolizumab
- Where
- 27 sites in United States, Brazil and 9 more
- Volunteers
- 66 people
- Sponsor
- Merck Sharp & Dohme LLC
Multiple Myeloma, Leukemia
Observational Study in Participants With Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) in Latin America
The primary purpose of the study is to quantify participants' demographic parameters, country standard therapies, treatment patterns and outcomes among participants with chronic lymphocytic leukemia (CLL), multiple myeloma (MM)…
- Conditions
- Multiple Myeloma, Leukemia, Lymphoid, Lymphoma
- Trial name
- HOLA (NCT02559583)
- Testing
- Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), Non-Hodgkin's lymphoma (NHL)
- Where
- 23 sites in Argentina, Brazil and 5 more
- Volunteers
- 5,443 people
- Sponsor
- Janssen-Cilag Ltd.
Leukemia, Lymphoblastic, Acute, Pediatric
Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)
Clofarabine (injection) is approved by the Food and Drug Administration (FDA) for the treatment of pediatric patients 1 to 21 years old with relapsed acute lymphoblastic leukemia (ALL) who have had at least 2 prior treatment…
- Trial name
- NCT00042341
- Testing
- clofarabine (IV formulation)
- Where
- 14 sites in United States
- Volunteers
- 60 people
- Sponsor
- Genzyme, a Sanofi Company
Diffuse Large B-cell Lymphoma
Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients…
- Trial name
- NCT02900651
- Testing
- MAK683
- Where
- 16 sites in United States, Canada and 8 more
- Volunteers
- 139 people
- Sponsor
- Novartis Pharmaceuticals
Leukemia, Lymphoma
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
RATIONALE: Biological therapies such as denileukin diftitox may be able to deliver cancer-killing substances directly to non-Hodgkin's lymphoma cells.
- Trial name
- NCT00026429
- Testing
- denileukin diftitox
- Where
- 6 sites in United States
- Sponsor
- Pharmatech Oncology
Solid Tumor, Lymphoma, Malignant
A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or Lymphoma
The purpose of this study is to assess the pharmacokinetics (PK) of enzastaurin and its metabolites in native Chinese participants with advanced and/or metastatic solid tumors or lymphoma.
- Trial name
- NCT01432951
- Testing
- Enzastaurin
- Where
- 3 sites in China
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
B-cell Non-Hodgkin's Lymphoma
A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma
This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.
- Trial name
- NCT06104553
- Testing
- SHR-A1912; R-Chemo
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Non-Hodgkin's Lymphoma, Lymphoma, B-cell
Phase II Study of ONTAK in Previously Treated Patients With Low-grade Non-Hodgkin's Lymphoma (NHL)
The purpose of this study is to look at the safety and effectiveness of ONTAK in previously treated patients with NHL.
- Conditions
- Non-Hodgkin's Lymphoma, Lymphoma, B-cell, Lymphoma, Low-grade
- Trial name
- NCT00051025
- Testing
- ONTAK
- Where
- 2 sites in United States
- Volunteers
- 9 people
- Sponsor
- Eisai Inc.
CLL / SLL, CLL (Chronic Lymphocytic Leukemia)
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
This Phase 1, open-label, multicenter study is evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of lonitoclax (ZE50-0134) in adults with relapsed or refractory chronic…
- Conditions
- CLL / SLL, CLL (Chronic Lymphocytic Leukemia), SLL (Small Lymphocytic Lymphoma), Marginal Zone Lymphoma(MZL)
- Trial name
- NCT06708897
- Testing
- Lonitoclax (ZE50-0134)
- Where
- 5 sites in United States
- Volunteers
- 84 people
- Sponsor
- Lomond Therapeutics Holdings, Inc.
Alzheimer's Disease
Safety and Tolerability Study in Patients With Mild to Moderate Alzheimer's Disease (AD)
This study will evaluate the safety and tolerability and Aß-specific antibody response of CAD106 in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT00411580
- Testing
- CAD106
- Where
- 3 sites in Sweden
- Volunteers
- 58 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoblastic Leukemia, Acute Adult
Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
Evaluate the safety (P-I), pharmacokinetics and anti-tumor effect of immunotherapy of autologous T cells genetically modified to express anti-CD19 chimeric antigen receptor (CAR) (TBI-1501) for relapsed or refractory CD19+ B-cell…
- Trial name
- TBI-1501 (NCT03155191)
- Testing
- TBI-1501
- Where
- 11 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Takara Bio Inc.
Leukemia, Lymphocytic, Chronic, B-Cell
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies
The purpose of this study is to compare the efficacy and safety of liso-cel vs Investigator's Choice options (idelalisib + rituximab or bendamustine + rituximab) in adult participants with R/R CLL or SLL, whose disease has failed…
- Trial name
- NCT06205290
- Testing
- Liso-cel, Idelalisib, Rituximab
- Where
- 48 sites in United States, Austria and 9 more
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
Follicular Lymphoma
A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel…
- Trial name
- NCT06794268
- Testing
- Lisocabtagene maraleucel
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.